RenovoRx (RNXT) Competitors $1.27 +0.08 (+6.72%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNXT vs. FGEN, CYTH, NNVC, CALC, IKT, OTLK, RPTX, VTYX, IFRX, and CNTXShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include FibroGen (FGEN), Cyclo Therapeutics (CYTH), NanoViricides (NNVC), CalciMedica (CALC), Inhibikase Therapeutics (IKT), Outlook Therapeutics (OTLK), Repare Therapeutics (RPTX), Ventyx Biosciences (VTYX), InflaRx (IFRX), and Context Therapeutics (CNTX). These companies are all part of the "medical" sector. RenovoRx vs. FibroGen Cyclo Therapeutics NanoViricides CalciMedica Inhibikase Therapeutics Outlook Therapeutics Repare Therapeutics Ventyx Biosciences InflaRx Context Therapeutics RenovoRx (NASDAQ:RNXT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation. Which has more volatility and risk, RNXT or FGEN? RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Is RNXT or FGEN more profitable? RenovoRx has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -205.96% -110.01% FibroGen -67.66%N/A -36.17% Do institutionals & insiders hold more shares of RNXT or FGEN? 3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in RNXT or FGEN? FibroGen received 335 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.71% of users gave FibroGen an outperform vote while only 44.44% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformRenovoRxOutperform Votes844.44% Underperform Votes1055.56% FibroGenOutperform Votes34360.71% Underperform Votes22239.29% Which has preferable earnings & valuation, RNXT or FGEN? RenovoRx has higher earnings, but lower revenue than FibroGen. RenovoRx is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRxN/AN/A-$10.23M-$0.57-2.12FibroGen$147.75M0.24-$284.23M-$1.23-0.28 Does the media prefer RNXT or FGEN? In the previous week, FibroGen had 1 more articles in the media than RenovoRx. MarketBeat recorded 5 mentions for FibroGen and 4 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.27 beat FibroGen's score of 0.80 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RNXT or FGEN? RenovoRx currently has a consensus target price of $6.13, suggesting a potential upside of 406.20%. Given RenovoRx's stronger consensus rating and higher possible upside, research analysts clearly believe RenovoRx is more favorable than FibroGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryRenovoRx beats FibroGen on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.04M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-2.1210.78135.4117.82Price / SalesN/A243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book-4.325.474.674.68Net Income-$10.23M$153.61M$119.07M$226.08M7 Day Performance11.01%-2.00%-1.83%-1.04%1 Month Performance21.62%-7.46%-3.60%1.04%1 Year Performance94.78%31.82%31.66%26.28% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx2.6223 of 5 stars$1.27+6.7%$6.13+382.3%+98.7%$30.48MN/A-2.236News CoveragePositive NewsFGENFibroGen2.4563 of 5 stars$0.37+4.7%N/A-33.8%$36.92M$147.75M-0.28486Analyst RevisionGap DownCYTHCyclo Therapeutics2.7699 of 5 stars$0.68-4.1%$0.95+39.7%-47.9%$19.56M$1.08M0.009News CoverageGap UpNNVCNanoViricidesN/A$1.31-1.2%N/A+15.8%$18.34MN/A-1.7420Analyst DowngradeCALCCalciMedica3.0773 of 5 stars$3.40-1.4%$19.33+468.6%+10.6%$45.83MN/A0.0030IKTInhibikase Therapeutics2.7555 of 5 stars$1.85-6.6%$6.50+251.4%+130.1%$13.80M$260,000.000.008OTLKOutlook Therapeutics1.2029 of 5 stars$5.13-2.8%$48.20+839.6%-40.0%$121.38MN/A-0.4920RPTXRepare Therapeutics2.672 of 5 stars$2.85+0.4%$10.00+250.9%-44.7%$121.15M$51.13M0.00180VTYXVentyx Biosciences2.4892 of 5 stars$1.70-1.5%$10.00+490.0%-27.1%$119.85MN/A-0.7373IFRXInflaRx3.0863 of 5 stars$1.98-2.9%$8.00+304.0%+34.2%$116.58M$70,000.000.0060Gap UpCNTXContext Therapeutics2.0835 of 5 stars$1.54-5.5%$6.25+305.8%+81.1%$115.50MN/A-1.797Gap Down Related Companies and Tools Related Companies FGEN Alternatives CYTH Alternatives NNVC Alternatives CALC Alternatives IKT Alternatives OTLK Alternatives RPTX Alternatives VTYX Alternatives IFRX Alternatives CNTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNXT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
